This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reubi, J. C. Articles by Schaer, J.-C. Search for Related Content PubMed PubMed Citation Articles by Reubi, J. C. Articles by Schaer, J.-C.

Y₁-Mediated Effect of Neuropeptide Y in Cancer

Breast Carcinomas as Targets

Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland

Overexpression of selected peptide receptors in human tumors has been shown to represent clinically relevant targets for cancer diagnosis and therapy. Neuropeptide Y (NPY) is a peptide neurotransmitter mediating feeding behavior and vasoconstriction. It has never been shown to be involved in human cancer. We show here, using in vitro receptor autoradiography, a NPY receptor incidence of 85% in primary human breast carcinomas (n = 95) and of 100% in lymph node metastases of receptor-positive primaries (n = 27), predominantly as Y₁ subtype, whereas non-neoplastic human breast expressed Y₂ preferentially. Y₁ mRNA was detected in Y₁-expressing tumors by in situ hybridization, whereas Y₂ mRNA was found in normal breast tissue. The strong predominance of Y₁ in breast carcinomas compared with Y₂ in normal breast suggests that neoplastic transformation can switch the NPY receptor expression from Y₂ to Y₁ subtype. Moreover, in Y₁-expressing human SK-N-MC tumor cells, an NPY-induced, dose-dependent inhibition of tumor cell growth of >40% was observed, suggesting a functional role of NPY in cancer, mediated by Y₁. NPY should therefore be added to the list of small regulatory peptides related to cancer. The high incidence of Y₁ in in situ, invasive, and metastatic breast cancers allows for the possibility to target them for diagnosis and therapy with NPY analogues.

This article has been cited by other articles:

				M. Korner, B. Waser, and J. C. Reubi High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors Clin. Cancer Res., August 15, 2008; 14(16): 5043 - 5049. [Abstract] [Full Text] [PDF]

				D. Wild, M. Behe, A. Wicki, D. Storch, B. Waser, M. Gotthardt, B. Keil, G. Christofori, J. C. Reubi, and H. R. Macke [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting J. Nucl. Med., December 1, 2006; 47(12): 2025 - 2033. [Abstract] [Full Text] [PDF]

				H. Amlal, S. Faroqui, A. Balasubramaniam, and S. Sheriff Estrogen Up-regulates Neuropeptide Y Y1 Receptor Expression in a Human Breast Cancer Cell Line. Cancer Res., April 1, 2006; 66(7): 3706 - 3714. [Abstract] [Full Text] [PDF]

				M. Ruscica, E. Dozio, S. Boghossian, G. Bovo, V. Martos Riano, M. Motta, and P. Magni Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells Endocrinology, March 1, 2006; 147(3): 1466 - 1473. [Abstract] [Full Text] [PDF]

				J. Kitlinska, K. Abe, L. Kuo, J. Pons, M. Yu, L. Li, J. Tilan, L. Everhart, E. W. Lee, Z. Zukowska, et al. Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest-Derived Tumors Cancer Res., March 1, 2005; 65(5): 1719 - 1728. [Abstract] [Full Text] [PDF]

				J. C. Reubi, H. R. Macke, and E. P. Krenning Candidates for Peptide Receptor Radiotherapy Today and in the Future J. Nucl. Med., January 1, 2005; 46(1_suppl): 67S - 75S. [Abstract] [Full Text] [PDF]

				M. Korner, B. Waser, and J. C. Reubi High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia Clin. Cancer Res., December 15, 2004; 10(24): 8426 - 8433. [Abstract] [Full Text] [PDF]

				S.-J. Gao, J.-H. Deng, and F.-C. Zhou Productive Lytic Replication of a Recombinant Kaposi's Sarcoma-Associated Herpesvirus in Efficient Primary Infection of Primary Human Endothelial Cells J. Virol., September 15, 2003; 77(18): 9738 - 9749. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				J. C. Reubi, B. Waser, W. Vale, and J. Rivier Expression of CRF1 and CRF2 Receptors in Human Cancers J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3312 - 3320. [Abstract] [Full Text] [PDF]